Meta‐analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists
Identifieur interne : 001E99 ( Istex/Corpus ); précédent : 001E98; suivant : 001F00Meta‐analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists
Auteurs : Gregor Simonis ; Joerg T. Fuhrmann ; Ruth H. StrasserSource :
- Movement Disorders [ 0885-3185 ] ; 2007-10-15.
English descriptors
Abstract
Valvular heart disease in patients being treated with ergot‐derivative dopamine agonists (Ergot‐DA) for Parkinson's disease has been reported to occur as a consequence of serotonine receptor stimulation. Goal of this analysis was to estimate the incidence of those changes from recently published studies and to determine its clinical relevance. Medline searches were performed to identify cross‐sectional, echocardiographic studies comparing patients treated with dopamine agonists or controls, in terms of valvular changes. Observational studies of valve changes in Parkinsonian patients were used to estimate the incidence of severe valvulopathy. The results from 7 cross‐sectional studies including 477 patients treated with Ergot‐DA, 127 patients with non‐Ergot‐DA, and 364 control patients were analyzed. Moderate‐to‐severe valvular changes were detected in 26% of patients treated with Ergot‐DA, 10% of patients treated with non‐Ergot DA, and 10% of control patients. Severe valvulopathy was less than 1% both in cross‐sectional and observational studies. The high rate of moderate valvular changes in patients treated with Ergot‐DA suggests that close surveillance of the patients is required. Severe valvulopathy was less than 1% in the studies analyzed. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21639
Links to Exploration step
ISTEX:22013580F8E1860DF038E7D18AC6F7212F4106FELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Meta‐analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists</title><author><name sortKey="Simonis, Gregor" sort="Simonis, Gregor" uniqKey="Simonis G" first="Gregor" last="Simonis">Gregor Simonis</name><affiliation><mods:affiliation>Department of Medicine/Cardiology, Heart Center, University of Technology, Dresden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Fuhrmann, Joerg T" sort="Fuhrmann, Joerg T" uniqKey="Fuhrmann J" first="Joerg T." last="Fuhrmann">Joerg T. Fuhrmann</name><affiliation><mods:affiliation>Department of Medicine/Cardiology, Heart Center, University of Technology, Dresden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Strasser, Ruth H" sort="Strasser, Ruth H" uniqKey="Strasser R" first="Ruth H." last="Strasser">Ruth H. Strasser</name><affiliation><mods:affiliation>Department of Medicine/Cardiology, Heart Center, University of Technology, Dresden, Germany</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:22013580F8E1860DF038E7D18AC6F7212F4106FE</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21639</idno><idno type="url">https://api.istex.fr/document/22013580F8E1860DF038E7D18AC6F7212F4106FE/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001E99</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Meta‐analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists</title><author><name sortKey="Simonis, Gregor" sort="Simonis, Gregor" uniqKey="Simonis G" first="Gregor" last="Simonis">Gregor Simonis</name><affiliation><mods:affiliation>Department of Medicine/Cardiology, Heart Center, University of Technology, Dresden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Fuhrmann, Joerg T" sort="Fuhrmann, Joerg T" uniqKey="Fuhrmann J" first="Joerg T." last="Fuhrmann">Joerg T. Fuhrmann</name><affiliation><mods:affiliation>Department of Medicine/Cardiology, Heart Center, University of Technology, Dresden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Strasser, Ruth H" sort="Strasser, Ruth H" uniqKey="Strasser R" first="Ruth H." last="Strasser">Ruth H. Strasser</name><affiliation><mods:affiliation>Department of Medicine/Cardiology, Heart Center, University of Technology, Dresden, Germany</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-10-15">2007-10-15</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="1936">1936</biblScope><biblScope unit="page" to="1942">1942</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">22013580F8E1860DF038E7D18AC6F7212F4106FE</idno><idno type="DOI">10.1002/mds.21639</idno><idno type="ArticleID">MDS21639</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cabergoline</term><term>Parkinson's disease</term><term>Pergolide</term><term>heart valve abnormalities</term><term>meta analysis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Valvular heart disease in patients being treated with ergot‐derivative dopamine agonists (Ergot‐DA) for Parkinson's disease has been reported to occur as a consequence of serotonine receptor stimulation. Goal of this analysis was to estimate the incidence of those changes from recently published studies and to determine its clinical relevance. Medline searches were performed to identify cross‐sectional, echocardiographic studies comparing patients treated with dopamine agonists or controls, in terms of valvular changes. Observational studies of valve changes in Parkinsonian patients were used to estimate the incidence of severe valvulopathy. The results from 7 cross‐sectional studies including 477 patients treated with Ergot‐DA, 127 patients with non‐Ergot‐DA, and 364 control patients were analyzed. Moderate‐to‐severe valvular changes were detected in 26% of patients treated with Ergot‐DA, 10% of patients treated with non‐Ergot DA, and 10% of control patients. Severe valvulopathy was less than 1% both in cross‐sectional and observational studies. The high rate of moderate valvular changes in patients treated with Ergot‐DA suggests that close surveillance of the patients is required. Severe valvulopathy was less than 1% in the studies analyzed. © 2007 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Gregor Simonis MD</name><affiliations><json:string>Department of Medicine/Cardiology, Heart Center, University of Technology, Dresden, Germany</json:string></affiliations></json:item><json:item><name>Joerg T. Fuhrmann</name><affiliations><json:string>Department of Medicine/Cardiology, Heart Center, University of Technology, Dresden, Germany</json:string></affiliations></json:item><json:item><name>Ruth H. Strasser MD</name><affiliations><json:string>Department of Medicine/Cardiology, Heart Center, University of Technology, Dresden, Germany</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>heart valve abnormalities</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Cabergoline</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Pergolide</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>meta analysis</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Valvular heart disease in patients being treated with ergot‐derivative dopamine agonists (Ergot‐DA) for Parkinson's disease has been reported to occur as a consequence of serotonine receptor stimulation. Goal of this analysis was to estimate the incidence of those changes from recently published studies and to determine its clinical relevance. Medline searches were performed to identify cross‐sectional, echocardiographic studies comparing patients treated with dopamine agonists or controls, in terms of valvular changes. Observational studies of valve changes in Parkinsonian patients were used to estimate the incidence of severe valvulopathy. The results from 7 cross‐sectional studies including 477 patients treated with Ergot‐DA, 127 patients with non‐Ergot‐DA, and 364 control patients were analyzed. Moderate‐to‐severe valvular changes were detected in 26% of patients treated with Ergot‐DA, 10% of patients treated with non‐Ergot DA, and 10% of control patients. Severe valvulopathy was less than 1% both in cross‐sectional and observational studies. The high rate of moderate valvular changes in patients treated with Ergot‐DA suggests that close surveillance of the patients is required. Severe valvulopathy was less than 1% in the studies analyzed. © 2007 Movement Disorder Society</abstract><qualityIndicators><score>5.381</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1296</abstractCharCount><pdfWordCount>3197</pdfWordCount><pdfCharCount>21220</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>182</abstractWordCount></qualityIndicators><title>Meta‐analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists</title><genre><json:string>Serial article</json:string></genre><host><volume>22</volume><pages><total>7</total><last>1942</last><first>1936</first></pages><issn><json:string>0885-3185</json:string></issn><issue>13</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/mds.21639</json:string></doi><id>22013580F8E1860DF038E7D18AC6F7212F4106FE</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/22013580F8E1860DF038E7D18AC6F7212F4106FE/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/22013580F8E1860DF038E7D18AC6F7212F4106FE/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/22013580F8E1860DF038E7D18AC6F7212F4106FE/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Meta‐analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2007</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Meta‐analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists</title><author><persName><forename type="first">Gregor</forename><surname>Simonis</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Department of Medicine and Cardiology, Dresden University of Technology, Fetscherstr. 76, 01307 Dresden, Germany</p></note><affiliation>Department of Medicine/Cardiology, Heart Center, University of Technology, Dresden, Germany</affiliation></author><author><persName><forename type="first">Joerg T.</forename><surname>Fuhrmann</surname></persName><affiliation>Department of Medicine/Cardiology, Heart Center, University of Technology, Dresden, Germany</affiliation></author><author><persName><forename type="first">Ruth H.</forename><surname>Strasser</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Medicine/Cardiology, Heart Center, University of Technology, Dresden, Germany</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-10-15"></date><biblScope unit="vol">22</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="1936">1936</biblScope><biblScope unit="page" to="1942">1942</biblScope></imprint></monogr><idno type="istex">22013580F8E1860DF038E7D18AC6F7212F4106FE</idno><idno type="DOI">10.1002/mds.21639</idno><idno type="ArticleID">MDS21639</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Valvular heart disease in patients being treated with ergot‐derivative dopamine agonists (Ergot‐DA) for Parkinson's disease has been reported to occur as a consequence of serotonine receptor stimulation. Goal of this analysis was to estimate the incidence of those changes from recently published studies and to determine its clinical relevance. Medline searches were performed to identify cross‐sectional, echocardiographic studies comparing patients treated with dopamine agonists or controls, in terms of valvular changes. Observational studies of valve changes in Parkinsonian patients were used to estimate the incidence of severe valvulopathy. The results from 7 cross‐sectional studies including 477 patients treated with Ergot‐DA, 127 patients with non‐Ergot‐DA, and 364 control patients were analyzed. Moderate‐to‐severe valvular changes were detected in 26% of patients treated with Ergot‐DA, 10% of patients treated with non‐Ergot DA, and 10% of control patients. Severe valvulopathy was less than 1% both in cross‐sectional and observational studies. The high rate of moderate valvular changes in patients treated with Ergot‐DA suggests that close surveillance of the patients is required. Severe valvulopathy was less than 1% in the studies analyzed. © 2007 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>heart valve abnormalities</term></item><item><term>Cabergoline</term></item><item><term>Pergolide</term></item><item><term>Parkinson's disease</term></item><item><term>meta analysis</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-03-16">Received</change><change when="2007-05-23">Registration</change><change when="2007-10-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/22013580F8E1860DF038E7D18AC6F7212F4106FE/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="130"><doi origin="wiley" registered="yes">10.1002/mds.v22:13</doi><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">13</numbering></numberingGroup><coverDate startDate="2007-10-15">15 October 2007</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="150" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21639</doi><idGroup><id type="unit" value="MDS21639"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2007 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2007-03-16"></event><event type="manuscriptAccepted" date="2007-05-23"></event><event type="firstOnline" date="2007-07-20"></event><event type="publishedOnlineFinalForm" date="2007-10-26"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2007-07-20"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1936</numbering><numbering type="pageLast">1942</numbering></numberingGroup><correspondenceTo>Department of Medicine and Cardiology, Dresden University of Technology, Fetscherstr. 76, 01307 Dresden, Germany</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21639.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="19"></count><count type="wordTotal" number="3629"></count></countGroup><titleGroup><title type="main" xml:lang="en">Meta‐analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists</title><title type="short" xml:lang="en">Dopamine Agonists and Heart Valve Abnormalities</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Gregor</givenNames><familyName>Simonis</familyName><degrees>MD</degrees></personName><contactDetails><email>gsimonis@gmx.de</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Joerg T.</givenNames><familyName>Fuhrmann</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Ruth H.</givenNames><familyName>Strasser</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="DE" type="organization"><unparsedAffiliation>Department of Medicine/Cardiology, Heart Center, University of Technology, Dresden, Germany</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">heart valve abnormalities</keyword><keyword xml:id="kwd2">Cabergoline</keyword><keyword xml:id="kwd3">Pergolide</keyword><keyword xml:id="kwd4">Parkinson's disease</keyword><keyword xml:id="kwd5">meta analysis</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Valvular heart disease in patients being treated with ergot‐derivative dopamine agonists (Ergot‐DA) for Parkinson's disease has been reported to occur as a consequence of serotonine receptor stimulation. Goal of this analysis was to estimate the incidence of those changes from recently published studies and to determine its clinical relevance. Medline searches were performed to identify cross‐sectional, echocardiographic studies comparing patients treated with dopamine agonists or controls, in terms of valvular changes. Observational studies of valve changes in Parkinsonian patients were used to estimate the incidence of severe valvulopathy. The results from 7 cross‐sectional studies including 477 patients treated with Ergot‐DA, 127 patients with non‐Ergot‐DA, and 364 control patients were analyzed. Moderate‐to‐severe valvular changes were detected in 26% of patients treated with Ergot‐DA, 10% of patients treated with non‐Ergot DA, and 10% of control patients. Severe valvulopathy was less than 1% both in cross‐sectional and observational studies. The high rate of moderate valvular changes in patients treated with Ergot‐DA suggests that close surveillance of the patients is required. Severe valvulopathy was less than 1% in the studies analyzed. © 2007 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Meta‐analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Dopamine Agonists and Heart Valve Abnormalities</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Meta‐analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists</title></titleInfo><name type="personal"><namePart type="given">Gregor</namePart><namePart type="family">Simonis</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Medicine/Cardiology, Heart Center, University of Technology, Dresden, Germany</affiliation><description>Correspondence: Department of Medicine and Cardiology, Dresden University of Technology, Fetscherstr. 76, 01307 Dresden, Germany</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Joerg T.</namePart><namePart type="family">Fuhrmann</namePart><affiliation>Department of Medicine/Cardiology, Heart Center, University of Technology, Dresden, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ruth H.</namePart><namePart type="family">Strasser</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Medicine/Cardiology, Heart Center, University of Technology, Dresden, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-10-15</dateIssued><dateCaptured encoding="w3cdtf">2007-03-16</dateCaptured><dateValid encoding="w3cdtf">2007-05-23</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">1</extent><extent unit="references">19</extent><extent unit="words">3629</extent></physicalDescription><abstract lang="en">Valvular heart disease in patients being treated with ergot‐derivative dopamine agonists (Ergot‐DA) for Parkinson's disease has been reported to occur as a consequence of serotonine receptor stimulation. Goal of this analysis was to estimate the incidence of those changes from recently published studies and to determine its clinical relevance. Medline searches were performed to identify cross‐sectional, echocardiographic studies comparing patients treated with dopamine agonists or controls, in terms of valvular changes. Observational studies of valve changes in Parkinsonian patients were used to estimate the incidence of severe valvulopathy. The results from 7 cross‐sectional studies including 477 patients treated with Ergot‐DA, 127 patients with non‐Ergot‐DA, and 364 control patients were analyzed. Moderate‐to‐severe valvular changes were detected in 26% of patients treated with Ergot‐DA, 10% of patients treated with non‐Ergot DA, and 10% of control patients. Severe valvulopathy was less than 1% both in cross‐sectional and observational studies. The high rate of moderate valvular changes in patients treated with Ergot‐DA suggests that close surveillance of the patients is required. Severe valvulopathy was less than 1% in the studies analyzed. © 2007 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>heart valve abnormalities</topic><topic>Cabergoline</topic><topic>Pergolide</topic><topic>Parkinson's disease</topic><topic>meta analysis</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>13</number></detail><extent unit="pages"><start>1936</start><end>1942</end><total>7</total></extent></part></relatedItem><identifier type="istex">22013580F8E1860DF038E7D18AC6F7212F4106FE</identifier><identifier type="DOI">10.1002/mds.21639</identifier><identifier type="ArticleID">MDS21639</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E99 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001E99 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:22013580F8E1860DF038E7D18AC6F7212F4106FE
|texte= Meta‐analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists
}}
| This area was generated with Dilib version V0.6.23. |  |